| Jenny Chaplin |
Jenny Chaplin is currently the Vice President-Strategic Operations at Bellicum Pharmaceuticals, Inc. She previously worked at Pfizer Inc. She obtained an undergraduate degree from the University of the Witwatersrand. |
| Joseph Howard Senesac |
Joseph Howard Senesac is currently the Senior VP-Technical Operations & Quality at Bellicum Pharmaceuticals, Inc. He previously worked as the Associate Director-Process Sciences at Introgen Therapeutics, Inc., the Senior Director-Biologics Manufacturing at Precigen, Inc., the Principal at Rhone-Poulenc Rorer, Inc., and the Principal at Promega Corp. He completed his undergraduate degree at Knox College and holds an MBA from The University of Colorado. |
| Dave Maggio |
Dave Maggio is currently the Chief Executive Officer at Bellicum Pharmaceuticals, Inc., President, CEO, Secretary & Treasurer at Metacrine, Inc., Director at Armanino LLP, and Chief Financial Officer at Nabriva Therapeutics Plc. He previously worked as a Director at TG Energy Industrial Services LLC from 2013 to 2018. Maggio received an undergraduate degree from Louisiana State University. |
| J. Henri Bayle |
J. Henri Bayle is currently working as the Vice President-Research at Bellicum Pharmaceuticals, Inc. He completed his undergraduate degree from the University of Alberta and his doctorate from Princeton University. |
| Richard A. Fair |
Richard A. Fair is currently the Director at Bellicum Pharmaceuticals, Inc. He previously worked as an Independent Director at Clovis Oncology, Inc. from 2018 to 2023 and as the SVP & Head-Therapeutic Oncology Global Product at Genentech, Inc. from 2014 to 2017. He also held the position of Franchise Head-Hematology at Roche Pharma (Schweiz) AG. Mr. Fair completed his undergraduate degree at the University of Michigan in 1990 and obtained an MBA from Columbia Business School in 1992. |
